Bartolomé Carrilero

Bartolomé Carrilero

Auto-generated profile, based on publicly available information

Bartolomé Carrilero

Unidad de Medicina Tropical, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain

Research Focus & Metrics

Representative Publications

View All Publications
11 June 2010 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
LMLaura Murcia
Laura Murcia
BCBartolomé Carrilero
Bartolomé Carrilero
MMM. Jose Muñoz
M. Jose Muñoz
MIM. Asunción Iborra
M. Asunción Iborra
MSManuel Segovia
Manuel Segovia
This prospective study focused on the evaluation of antiparasitic therapy in chronic Chagas’ disease, monitored by PCR. One hundred and eighty-one patients, all seropositive for Trypanosoma cruzi infection, underwent specific chemotherapy with benznidazole. Twelve patients were classified as young (2–19 years), 122 patients were classified as adults (20–39 years) and 47 patients were classified as seniors (≥40 years). In total, 116 (64%) were asymptomatic and 65 (36%) were symptomatic. Patients were monitored for 90, 150 and 420 days after treatment by PCR and serology. Before treatment, 68% had a positive PCR result. PCR positivity was significantly more frequent in patients aged 2–19 years (P = 0.0007) and in short-term immigrants (P = 0.0076). No differences in PCR sensitivity were observed between samples of patients with chronic symptomatic or indeterminate Chagas’ disease. All patients presented an early conversion of PCR results 90 days post-treatment. However, at the end of the follow-up period PCR had become positive in four patients (4 out of 58 patients; 6.9%) who had strictly adhered to the treatment and in one who did not complete the treatment. Only one patient showed an alternating PCR during follow-up. We conclude that PCR is a useful tool for the early detection of parasite susceptibility to benznidazole and for the post-treatment parasitological follow-up of patients with chronic Chagas' disease.

24 October 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
LMLaura Murcia
Laura Murcia
BCBartolomé Carrilero
Bartolomé Carrilero
MMM. Jose Munoz-Davila
M. Jose Munoz-Davila
MTM. Carmen Thomas
M. Carmen Thomas
MLManuel Carlos López
Manuel Carlos López
MSManuel Segovia
Manuel Segovia
Background. In this longitudinal cohort study we evaluated the congenital transmission of Chagas disease (CD) in a nonendemic area. The aim of this work was to analyze the predictive value of a Trypanosoma cruzi–positive polymerase chain reaction (PCR) result in pregnant women for the diagnosis of vertical transmission and to evaluate the use of PCR as a tool for early detection of infection. Methods. The offspring of 59 seropositive pregnant mothers were followed up. The parasitological status of mothers was studied by PCR in a total of 64 pregnancies; 10 of these women had received treatment before pregnancy. Sixty-five infants (including a pair of twins) were monitored at 0, 6, 9, and 12 months of age by PCR and serology. In cases of congenital transmission, hemoculture and parasite lineage typing were performed. Results. Nine infants had acquired CD congenitally. This represents a transmission rate of 13.8% among seropositive mothers (9 infected newborns of 65 total live births). All infants were infected with T. cruzi discrete typing unit V strain. A statistically significant correlation was found between T. cruzi vertical transmission and a positive PCR result during pregnancy (31%; 9 infected newborns in 29 live births). No infected infants were detected among 10 mothers who were treated before they became pregnant, compared with 16.4% (9 of 55 live births) among untreated mothers. Conclusions. PCR is a useful tool for the detection of congenital CD, and the treatment of infected women of childbearing age seems to be useful for preventing vertical transmission.

31 July 2011 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AFAna Fernández-Villegas
Ana Fernández-Villegas
Maria Jesús PinazoMaria Jesús Pinazo
Maria Jesús Pinazo
CMConcepción Marañón
Concepción Marañón
MTM. Carmen Thomas
M. Carmen Thomas
EPElizabeth Posada
Elizabeth Posada
MLManuel Carlos López
Manuel Carlos López
Background: Conventional serological tests, using total soluble proteins or a cocktail of recombinant proteins from T. cruzi as antigens, are highly sensitive for Chagas disease diagnosis. This type of tests, however, does not seem to be reliable tools for short- and medium-term monitoring of the evolution of patients after antiparasitic treatment. The aim of the present study was to search for immunological markers that could be altered in the sera from Chagas disease patients after benznidazole treatment, and therefore have a potential predictive diagnostic value. Methods: We analyzed the reactivity of sera from chagasic patients during different clinical phases of the disease against a series of immunodominant antigens, known as KMP11, PFR2, HSP70 and Tgp63. The reactivity of the sera from 46 adult Chronic Chagas disease patients living in a non-endemic country without vector transmission of T. cruzi (15 patients in the indeterminate stage, 16 in the cardiomiopathy stage and 16 in the digestive stage) and 22 control sera from non-infected subjects was analyzed. We also analyzed the response dynamics of sera from those patients who had been treated with benznidazole. Results: Regardless of the stage of the sickness, the sera from chagasic patients reacted against KMP11, HSP70, PFR2 and Tgp63 recombinant proteins with statistical significance relative to the reactivity against the same antigens by the sera from healthy donors, patients with autoimmune diseases or patients suffering from tuberculosis, leprosy or malaria. Shortly after benznidazole treatment, a statistically significant decrease in reactivity against KMP11, HSP70 and PFR2 was observed (six or nine month). It was also observed that, following benznidazole treatment, the differential reactivity against these antigens co-relates with the clinical status of the patients. Conclusions: The recombinant antigens KMP11, PFR2, Tgp63 and HSP70 are recognized by Chagas disease patients' sera at any clinical stage of the disease. Shortly after benznidazole treatment, a drop in reactivity against three of these antigens is produced in an antigen-specific manner. Most likely, analysis of the reactivity against these recombinant antigens may be useful for monitoring the effectiveness of benznidazole treatment.

1 December 2011 in HIV Research & Clinical Practice
Verified
Journal Article
Closed access
JPJose A Perez-Molina
Jose A Perez-Molina
ARAzucena Rodríguez-Guardado
Azucena Rodríguez-Guardado
ASAntoni Soriano-Arandes
Antoni Soriano-Arandes
Maria Jesús PinazoMaria Jesús Pinazo
Maria Jesús Pinazo
BCBartolomé Carrilero
Bartolomé Carrilero
IHInternational Health])
International Health])
As a result of population migration, Chagas disease is no longer limited to the North and South American continents. In HIV-infected patients, chronic infection by Try-panosoma cruzi behaves as an opportunistic infection in severely immunosuppressed patients and is responsible for high morbidity and mortality. Unlike other opportunistic infections, information on the natural history, diagnosis, treatment, and prevention of Chagas disease is scarce. Spain has the highest number of cases of Chagas disease outside the North and South American continents, and coinfection with HIV is increasingly prevalent. In this article, the Spanish Society for Tropical Medicine and International Health (Sociedad Española de Medicina Tropical y Salud Interna-cional) reviews the current situation of coinfection with HIV and T. cruzi infection and provides guidelines on the diagnosis, treatment, and prevention in areas where Cha-gas disease is not endemic. It also identifies areas of uncertainty where additional research is necessary.

15 April 2017 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
JMJose Mateus
Jose Mateus
EPElena Pérez-Antón
Elena Pérez-Antón
PLPaola Lasso
Paola Lasso
AMAdriana Egui Machado
Adriana Egui Machado
NRNubia Roa
Nubia Roa
ACAdriana Cuéllar
Adriana Cuéllar
Chagas disease is a chronic infection caused by Trypanosoma cruzi, an intracellular protozoan parasite. Chronic chagasic patients (CCPs) have dysfunctional CD8+ T cells that are characterized by impaired cytokine production, high coexpression of inhibitory receptors, and advanced cellular differentiation. Most patients diagnosed in the chronic phase of Chagas disease already exhibit heart involvement, and there is no vaccination that protects against the disease. Antiparasitic treatment is controversial as to its indication for this stage of the disease. There is a lack of biological markers to evaluate the effectiveness of antiparasitic treatment, and little is known about the effect of the treatment on CD8+ T cells. Thus, the aim of the current study was to analyze the early effects of antiparasitic treatment on CD8+ T cells from CCPs with asymptomatic clinical forms of disease. To evaluate the CD8+ T cell subsets, expression of inhibitory receptors, and functionality of T cells in CCPs, PBMCs were isolated. The results showed that treatment of CCPs with the asymptomatic form of the disease induces an increase in the frequency of CD8+ central memory T cells and terminal effector T cells, a decrease in the coexpression of inhibitory receptors, an improved Ag-specific CD8+ T cell response exhibited by the individual production of IFN-γ or IL-2, and a multifunctional CD8+ T cell profile of up to four functions (IFN-γ+IL-2+Perforin+Granzyme B+). These findings suggest that, in CCPs, antiparasitic treatment improved the quality of Ag-specific CD8+ T cell responses associated with a decrease in inhibitory receptor coexpression, which could serve as biomarkers for monitoring the effectiveness of antiparasitic treatment.